ONEatDC: The ONE Study ATDC Trial
Study Details
Study Description
Brief Summary
To collect evidence of the safety of administering autologous tolerogenic dendritic cells (ATDC) preparations to living-donor renal transplant recipients in the context of an international European Union funded consortium aimed at evaluationg cellular immunotherapy in solid organ transplantation (The ONE Study). It is anticipated that immune regulation induced by ATDC therapy can evntually be used to reduce the need for conventional immunosuppression in transplant recipients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
Decades of immunosuppressive drug development have produced an array of powerful pharmacological agents, but the various drawbacks associated with these treatments leaves considerable room for improvement. By harnessing the power of suppressive mechanisms in the human immune system, regulatory cell therapy may be able to support peripheral tolerance and induce a level of donor-specific unresponsiveness that allows for a reduction in the use of conventional immunosuppression in organ transplant recipients. Several alternative regulatory cell types have been identified as potential adjunct immunotherapies for solid organ transplantation and are now approaching a stage of development that would allow clinical testing in an early-stage trial. The ONE Study aims to answer the question as whether ATDC treatment, or immunoregulatory cell-based therapy in general, has any place in the clinical management of solid organ transplant recipients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ATDC Treatment ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation. Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below : Prednidolone : D 0: 500 mg IV D 1: 125 mg IV D 2 to 14: 20.0 mg/d Wk 3 to 4: 15.0 mg/d Wk 5 to 8: 10.0 mg/d Wk 9 to 12: 5.0 mg/d Wk 13 to 14: 2.5 mg/d Wk 15 to End:Cessation MMF (or biologic equiv.): D -7 to -2: 500 mg/d (250mg 2x/d) D -1 to 14: 2000 mg/d Wk 3 to 36: 1000 mg/d Wk 37 to 40: 750 mg/d Wk 41 to 44: 500 mg/d Wk 45 to 48: 250 mg/d Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction. Tacrolimus : ≤ 48 h pre-Tx to D 14: 3-12 ng/ml Wk 3 to 12: 3-10 ng/ml Wk 13 to 36: 3-8 ng/ml Wk 37 to End: 3-6 ng/ml |
Biological: ATDC_Nantes
ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.
Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)
|
Outcome Measures
Primary Outcome Measures
- Incidence of biopsy-confirmed acute rejection (BCAR) [60 weeks]
Secondary Outcome Measures
- Time to first acute rejection episode [60 weeks]
- Severity of acute rejection episodes [60 weeks]
based on response to treatment and histological scoring
- Total immunosuppressive burden [60 weeks]
assessed at last study visit
- Incidence of patients treated for subclinical acute rejection on the basis of histopathological findings [60 weeks]
- Prevention of chronic graft dysfunction (chronic rejection or IF/TA) [60 weeks]
assessed by clinical (impairment of GFR) and histopathological (Banff staging) measures.
- Incidence of post-transplant dialysis, inclusion on the transplant waiting list or re-transplantation following graft loss through rejection (acute or chronic). [60 weeks]
- Avoidance of drug-related complications by immunosuppressant reduction [60 weeks]
- Incidence of embolic pulmonary complications and other embolic events [60 weeks]
- Incidence of immunological reactions resulting in anaphylactoid reactions, immediate cardiovascular compromise or other acute organ failure [1 week]
- Biochemical disturbances caused by cell infusion [1 week]
- Over-suppression of the immune system assessed by the incidence of major and/or opportunistic infections, especially CMV, EBV and polyoma virus [1 week]
- Over-suppression of the immune system assessed by the incidence of neoplasia. [1 week]
- Immunological condition of study patients w [60 weeks]
an extensive immune monitoring program has been established in the ONE Study
Other Outcome Measures
- Incidence of malignancies arising directly from ATDC_Nantes [60 weeks]
- ii) incidence of autoimmune disorders [60 weeks]
- Incidence of inflammatory pathologies [60 weeks]
- Incidence of anaemia, cytopaenia or biochemical disturbances unrelated to the function of the transplanted kidney. [60 weeks]
- A Health-Economic Subproject will evaluate the health-related quality-of-life of trial patients using patient-reported outcome measures. [60weeks]
This subproject will also calculate the cost-effectiveness of ATDC_Nantes to review the financial implications of cellular immunotherapy as a practical and routine clinical prescription.
Eligibility Criteria
Criteria
RECIPIENT
Inclusion Criteria:
-
Chronic renal insufficiency necessitating kidney transplantation and approved to receive a primary kidney allograft from a living donor
-
Aged at least 18 years
-
Able to commence the immunosuppressive regimen at the protocol-specified time point
-
Willing and able to participate in The ONE Study IM and HEC subprojects
-
Eligible for leucapheresis prior to organ transplantation
-
Signed and dated written informed consent
Exclusion Criteria:
-
Patient has previously received any tissue or organ transplant other than the planned kidney graft
-
Known contraindication to the protocol-specified treatments / medications (like known allergies to heparin)
-
Genetically identical to the prospective organ donor at the HLA loci (A.B.DR 0 mismatch)
-
PRA grade > 0 within 6 months prior to enrolment
-
Previous treatment with any desensitisation procedure (with or without IVIg)
-
Concomitant malignancy or history of malignancy within 5 years prior to planned study entry (excluding successfully-treated non-metastatic basal/squamous cell carcinoma of the skin)
-
ABO incompatibility
-
Presence of DSA (donor specific antibodies) detected by luminex prior transplantation
-
Evidence of significant local or systemic infection
-
HIV-positive, EBV-negative or suffering chronic viral hepatitis, syphilis serology- positive
-
Significant liver disease, defined as persistently elevated AST and/or ALT levels > 2 x ULN (Upper Limit of Normal range)
-
Malignant or pre-malignant haematological conditions
-
Any uncontrolled medical condition or concurrent disease that could interfere with the study objectives
-
Any condition which, in the judgement of the Investigator, would place the subject at undue risk
-
Ongoing treatment with systemic immunosuppressive drugs at inclusion (despite corticoids lower than 10 mg)
-
Participation in another clinical trial during the study or within 28 days prior to planned study entry
-
Exposure to an investigational product during the study or within 28 days prior to planned study entry
-
Female patients of child-bearing potential with a positive pregnancy test at enrolment and F01
-
Female patients who are breast-feeding
-
All female patients of child-bearing potential* UNLESS:
-
The patient is willing to maintain a highly effective method of birth control** for the duration of the study
-
The career, lifestyle, or sexual orientation of the patient ensures that there is no risk of pregnancy for the duration of the study (at the discretion of the Investigator)
-
Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up visit schedule
-
Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel
-
Patients unable to freely give their informed consent (e.g. individuals under legal guardianship).
Criteria specific to the infusion of the ATDC_Nantes:
-
Any pro-coagulant disposition, as evidenced by a past history of thromboembolic disease or abnormal laboratory coagulation parameters which, in the judgement of the Investigator, would place the subject at undue risk
-
Any condition resulting in a substantial reduction in the volume of the pulmonary vasculature or an increase in the pulmonary vascular resistance. Any disease or disease process leading to substantially elevated pulmonary arterial pressure (as evidenced by electrocardiography, echocardiography, radiology or cardiac catheterisation) or right heart hypertrophy or dysfunction
-
Known atrial or ventricular septal defects posing a risk of paradoxical embolism of infused cells or cell aggregates
-
Known hypersensitivity to any component of the cell product or components used in the manufacture of the cell product.
DONOR
Inclusion Criteria:
-
Eligible for live kidney donation
-
Willing and able to provide a blood sample for The ONE Study IM Subproject
-
Willing to provide personal and medical/biological data for the trial analysis
-
Signed and dated written informed consent
Exclusion Criteria:
-
Genetically identical to the prospective organ recipient at the HLA loci (A.B.DR 0 mismatch)
-
Exposure to any investigational agents at the time of kidney donation, or within 28 days prior to kidney donation
-
Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel
-
Subjects unable to freely give their informed consent (e.g. individuals under legal guardianship).
-
ABO incompatibility
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Nantes University hospital | Nantes | France | 44093 |
Sponsors and Collaborators
- Nantes University Hospital
Investigators
- Study Director: Edward K Geissler, PhD, University Hospital Regensburg
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- RC13_0441